[Rheumatology : what's new in 2025]

In 2025, for rheumatoid arthritis (RA), new stratification criteria offer the opportunity to detect individuals at risk of developing the disease, and preventive treatments aimed at delaying its onset are being studied, but their benefit appears to be limited in time after discontinuation. For established RA, new therapeutic options are emerging for difficult-to-treat RA: anti-PD-1, GM-CSF (Granulocyte Macrophage Colony-Stimulating Factor) inhibitors, bispecific antibodies, as well as the first non-pharmacological treatment registered by the FDA using vagal neurostimulation. Finally, a new marker for RA, pentraxin 3, appears promising as a complement to existing inflammatory markers which are still imperfect.